STAC-9 is an experimental drug that was developed by GlaxoSmithKline as a small-molecule activator of the sirtuin subtype SIRT1, with potential applications in the treatment of diabetes.[1][2][3]
See also
References
- ^ US 9556201, Ng PY, Blum C, Mcpherson L, Perni RB, Vu CB, Ahmed MM, Disch JS, ”Bicyclic pyridines and analogs as sirtuin modulators.”, published 4 October 2012, assigned to Sitris Pharmaceuticals and GlaxoSmithKline
- ^ Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, et al. (March 2013). “Evidence for a common mechanism of SIRT1 regulation by allosteric activators”. Science. 339 (6124): 1216–9. Bibcode:2013Sci…339.1216H. doi:10.1126/science.1231097. PMC 3799917. PMID 23471411.
- ^ Thevis M, Schänzer W (March 2016). “Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis – Potential implications for sports drug testing programs”. Rapid Communications in Mass Spectrometry. 30 (5): 635–51. Bibcode:2016RCMS…30..635T. doi:10.1002/rcm.7470. PMID 26842585. S2CID 206444739.